Literature DB >> 19925038

Genotyping of CYP21A2 for congenital adrenal hyperplasia screening using allele-specific primer extension followed by bead array hybridization.

Yongtaek Oh1, Sung Won Park, Sung-Min Chun, Namkyoo Lim, Ki Sup Ahn, Jong-Ok Ka, Dong-Kyu Jin, Byoung-Don Han.   

Abstract

BACKGROUND: Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease caused by mutations in the CYP21A2 gene, which codes for steroid 21-hydroxylase. More than 90% of patients with CAH have mutations in CYP21A2 or have large deletions in the RCCX module on chromosome 6p21.3, which also includes the pseudogene CYP21A1P. Genotyping of CYP21A2 is required for diagnosis of CAH, but current genotyping methods, such as direct sequencing, allele-specific PCR amplification, or PCR amplification and restriction fragment length polymorphism (PCR-RFLP) still need further improvements to reduce test time and cost.
METHODS: We developed a novel CAH mutation screening method based on allele-specific primer extension (ASPE), followed by bead-array hybridization, for the ten major point mutation sites and the 8 bp deletion in CYP21A2, and a long PCR assay to detect large deletions between CYP21A1P and CYP21A2. After the first long PCR amplification, a second short PCR amplification was adapted to increase the ASPE efficiency. The total genotyping procedure takes approximately 8 hours.
RESULTS: Eighteen CAH patients and two controls were tested using the bead-array method. Homozygous or heterozygous large gene deletions and three point mutation sites were detected by this method, and most of the results were consistent with sequencing or PCR-RFLP analysis. Nine of the 18 patients had a large deletion in the RCCX module, which was not easily detected using the conventional genotyping method.
CONCLUSION: A novel CAH mutation screening method has been developed to detect ten point mutations and the 8 bp deletion in CYP21A2, as well as large deletions between CYP21A1P and CYP21A2. This novel genotyping strategy is superior to PCR-RFLP-based methods and equally as accurate as sequencing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925038     DOI: 10.1007/BF03256346

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  27 in total

Review 1.  The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency.

Authors:  Hsien-Hsiung Lee
Journal:  J Hum Genet       Date:  2004-01-17       Impact factor: 3.172

2.  Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency.

Authors:  Robert C Wilson; Saroj Nimkarn; Miro Dumic; Jihad Obeid; Maryam Razzaghy Azar; Maryam Azar; Hossein Najmabadi; Fatemeh Saffari; Maria I New
Journal:  Mol Genet Metab       Date:  2007-02-01       Impact factor: 4.797

3.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

4.  Cortisol and 17-hydroxyprogesterone kinetics in saliva after oral administration of hydrocortisone in children and young adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Michael Gröschl; Manfred Rauh; Helmuth G Dörr
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

5.  Molecular analysis of Japanese patients with steroid 21-hydroxylase deficiency.

Authors:  A Asanuma; T Ohura; E Ogawa; S Sato; Y Igarashi; Y Matsubara; K Iinuma
Journal:  J Hum Genet       Date:  1999       Impact factor: 3.172

6.  Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.

Authors:  N Krone; A Braun; A A Roscher; D Knorr; H P Schwarz
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

7.  Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency.

Authors:  Siegfried Kösel; Siegfried Burggraf; Ralph Fingerhut; Helmut G Dörr; Adelbert A Roscher; Bernhard Olgemöller
Journal:  Clin Chem       Date:  2004-12-17       Impact factor: 8.327

8.  Characterization of a novel DNA polymorphism in the human CYP21 gene and application for DNA diagnosis of congenital adrenal hyperplasia.

Authors:  Y H Lee; E S Park; S H Kang; H Kim; J Y Lee; J S Lee
Journal:  Clin Endocrinol (Oxf)       Date:  2000-10       Impact factor: 3.478

9.  Incidence of classical 21-hydroxylase deficiency and distribution of CYP21A2 mutations in Estonia.

Authors:  Kaur Liivak; Simon Tobi; Helene Schlecht; Vallo Tillmann
Journal:  Horm Res       Date:  2008-01-21

10.  Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene.

Authors:  Y Higashi; H Yoshioka; M Yamane; O Gotoh; Y Fujii-Kuriyama
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

View more
  1 in total

1.  Novel method to characterize CYP21A2 in Florida patients with congenital adrenal hyperplasia and commercially available cell lines.

Authors:  Christopher N Greene; Suzanne K Cordovado; Daniel P Turner; Lisa M Keong; Dorothy Shulman; Patricia W Mueller
Journal:  Mol Genet Metab Rep       Date:  2014-08-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.